אסופרים אס.קיי. 20 מג
k.s.kim international (sk- pharma) ltd., israel - esomeprazole as sodium - קפסולה קשיחה - esomeprazole as sodium 20 mg - esomeprazole
אסופרים אס.קיי. 40 מג
k.s.kim international (sk- pharma) ltd., israel - esomeprazole as sodium - קפסולה קשיחה - esomeprazole as sodium 40 mg - esomeprazole
דביגטרן אס.קיי 110 מג
k.s.kim international ltd - dabigatran etexilate - קפסולות - dabigatran etexilate 110 mg - dabigatran etexilate
דביגטרן אס.קיי 150 מג
k.s.kim international ltd - dabigatran etexilate - קפסולות - dabigatran etexilate 150 mg - dabigatran etexilate
דביגטרן אס.קיי 75 מג
k.s.kim international ltd - dabigatran etexilate - קפסולות - dabigatran etexilate 75 mg - dabigatran etexilate
אסופרים קונטרול 20 מג
k.s.kim international (sk- pharma) ltd., israel - esomeprazole as sodium - קפסולה קשיחה - esomeprazole as sodium 20 mg - esomeprazole
לוסנטיס
novartis israel ltd - ranibizumab - תמיסה להזרקה - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd).treatment of adult patients with visual impairment due to diabetic macular oedema (dme) .the treatment of visual impairement due to macular oedema secondary to retinal vein occulsion (rvo).the treatment of visual impaiment due to choroidal neovacularization (cnv) secondary to pathologic myopia (pm).
בסרמי 250 מקג 0.5 מל
aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b
בסרמי 500 מקג 0.5 מל
aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b
סנדאימון ניאורל 50 מג כמוסות
novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.